2022
Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV
Li G, Park LS, Lodi S, Logan RW, Cartwright EJ, Aoun-Barakat L, Casas JP, Dickerman BA, Rentsch CT, Justice AC, Hernán MA. Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV. AIDS 2022, 36: 1689-1696. PMID: 35848570, PMCID: PMC9444875, DOI: 10.1097/qad.0000000000003314.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsCohort StudiesCOVID-19COVID-19 TestingEmtricitabineHIV InfectionsHumansLamivudineMaleSARS-CoV-2TenofovirConceptsTDF/FTCTenofovir disoproxil fumarateCoronavirus disease 2019 (COVID-19) outcomesTAF/FTCAntiretroviral therapyTenofovir alafenamideDisoproxil fumarateRisk ratioAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionCOVID-19 ICU admissionsIntensive care unit admissionPrevious COVID-19 diagnosisSyndrome coronavirus 2 infectionCOVID-19-related hospitalizationVeterans Aging Cohort StudySARS-CoV-2 infectionCare unit admissionCoronavirus 2 infectionChronic kidney diseaseHIV viral loadGlomerular filtration rateAging Cohort StudyCorresponding risk ratioPooled logistic regression
2021
Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015
Sun J, Althoff KN, Jing Y, Horberg MA, Buchacz K, Gill MJ, Justice AC, Rabkin CS, Goedert JJ, Sigel K, Cachay E, Park L, Lim JK, Kim HN, Re V, Moore R, Sterling T, Peters MG, Achenbach CJ, Silverberg M, Thorne JE, Mayor AM, Crane HM, Kitahata MM, Klein M, Kirk GD. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. JAMA Network Open 2021, 4: e2037512. PMID: 33595662, PMCID: PMC7890526, DOI: 10.1001/jamanetworkopen.2020.37512.Peer-Reviewed Original ResearchConceptsHCC incidence ratesHigher HCC riskHepatitis C virusHepatitis B virusModern cART eraCD4 cell countIncidence rateCART eraHCC riskHepatocellular carcinomaCohort studyTriple infectionNorth American AIDS Cohort CollaborationCell countAvailable CD4 cell countHigher HIV RNA levelsLow CD4 cell countsCombination antiretroviral therapy eraDiagnosis of HCCAnti-HCV seropositivityAntiretroviral therapy eraHBV-HCV coinfectionRecent HIV RNAHIV RNA levelsHBV e antigen
2020
CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018
Lee J, Humes E, Hogan B, Buchacz K, Eron J, Gill M, Sterling T, Rebeiro P, Lima V, Mayor A, Silverberg M, Horberg M, Moore R, Althoff K, Benson C, Bosch R, Emory-Grady G, Mayer K, Grasso C, Hogg R, Harrigan P, Montaner J, Yip B, Zhu J, Salters K, Gabler K, Buchacz K, Li J, Gebo K, Johns R, Moore R, Carey J, Rodriguez B, Horberg M, Silverberg M, Thorne J, Brown T, Tien P, D’Souza G, Crouzat F, Loutfy M, Smith G, Gupta M, Klein M, Rabkin C, Kroch A, Burchell A, Betts A, Lindsay J, Nijhawan A, Hunter-Mellado R, Mayor A, Gill M, Martin J, Li J, Brooks J, Saag M, Mugavero M, Willig J, Bamford L, Karris M, Eron J, Napravnik S, Kitahata M, Crane H, Sterling T, Haas D, Rebeiro P, Turner M, Park L, Justice A, Moore R, Althoff K, Gange S, Kitahata M, Lee J, Saag M, Horberg M, Klein M, McKaig R, Freeman A, Moore R, Althoff K, Freeman A, Kitahata M, Van Rompaey S, Crane H, Morton L, McReynolds J, Lober W, Gange S, Lee J, Hogan B, You B, Humes E, Gerace L, Stewart C, Coburn S. CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018. Clinical Infectious Diseases 2020, 73: e2334-e2337. PMID: 33383586, PMCID: PMC8492212, DOI: 10.1093/cid/ciaa1904.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountHIVHIV InfectionsHumansPrescriptionsUnited StatesMortality, Health, and Substance Abuse by Religious Attendance Among HIV Infected Patients from the Veterans Aging Cohort Study
Doolittle BR, McGinnis K, Ransome Y, Fiellin D, Justice A. Mortality, Health, and Substance Abuse by Religious Attendance Among HIV Infected Patients from the Veterans Aging Cohort Study. AIDS And Behavior 2020, 25: 653-660. PMID: 32902769, DOI: 10.1007/s10461-020-03028-4.Peer-Reviewed Original ResearchConceptsCohort studyVeterans Aging Cohort StudyAging Cohort StudyAssociation of mortalitySmall cohort studiesUnhealthy alcohol useOverall drug useHIV/AIDSSmoking statusMortality riskHigh social supportDrug useBiological markersSubstance abuseLess marijuana useAlcohol usePast yearReligious attendanceLower depressionMarijuana useMortalitySocial supportAssociationAttendanceHCVFIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C
So-Armah KA, Lim JK, Re V, Tate JP, Chang CH, Butt AA, Gibert CL, Rimland D, Marconi VC, Goetz MB, Ramachandran V, Brittain E, Long M, Nguyen KL, Rodriguez-Barradas MC, Budoff MJ, Tindle HA, Samet JH, Justice AC, Freiberg MS, Team V. FIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C. Progress In Cardiovascular Diseases 2020, 63: 184-191. PMID: 32068085, PMCID: PMC7278895, DOI: 10.1016/j.pcad.2020.02.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsFemaleHealth StatusHeart FailureHepatitis CHIV InfectionsHIV Long-Term SurvivorsHumansIncidenceLiver CirrhosisMaleMiddle AgedPrognosisRisk AssessmentRisk FactorsSeverity of Illness IndexStroke VolumeTime FactorsUnited StatesVentricular Function, LeftVeterans HealthViral LoadConceptsType of HFIncident heart failureHeart failureHepatitis C statusAdvanced fibrosisLiver fibrosisEjection fractionHazard ratioC statusVeterans Aging Cohort StudyRisk of HFpEFLast clinic visitReduced ejection fractionAging Cohort StudyLiver fibrosis scoresPrevalent cardiovascular diseaseFirst HF eventProportional hazards modelIncident HFpEFHepatitis CClinic visitsCohort studyPrimary outcomeFibrosis scoreHF eventsReceipt and predictors of smoking cessation pharmacotherapy among veterans with and without HIV
Shahrir S, Crothers K, McGinnis KA, Chan KCG, Baeten JM, Wilson SM, Butt AA, Pisani MA, Baldassarri SR, Justice A, Williams EC. Receipt and predictors of smoking cessation pharmacotherapy among veterans with and without HIV. Progress In Cardiovascular Diseases 2020, 63: 118-124. PMID: 31987807, PMCID: PMC7251937, DOI: 10.1016/j.pcad.2020.01.003.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-HIV AgentsCardiovascular DiseasesFemaleHealth StatusHIV InfectionsHIV Long-Term SurvivorsHumansLongitudinal StudiesMaleMiddle AgedPreventive Health ServicesProspective StudiesProtective FactorsRisk AssessmentRisk FactorsRisk Reduction BehaviorSmokersSmokingSmoking CessationSmoking Cessation AgentsTime FactorsTreatment OutcomeUnited StatesVeterans HealthViral LoadConceptsNicotine replacement therapyVeterans Aging Cohort StudyMultivariable log-linear regression modelsPotential treatment disparitiesSmoking cessation pharmacotherapyPatient-level factorsAging Cohort StudyMental health disordersRates of receiptUninfected participantsUninfected patientsCardiovascular riskCessation pharmacotherapyCohort studyCurrent smokingHIV statusMultivariable analysisTreatment disparitiesReplacement therapyRelative riskHealth disordersPharmacotherapyPLWHSmokingHIV
2019
Improved discrimination of mortality with Veterans Aging Cohort Study (VACS) Index 2.0 in HIV-positive individuals
Tate JP, Sterne JAC, Justice AC. Improved discrimination of mortality with Veterans Aging Cohort Study (VACS) Index 2.0 in HIV-positive individuals. AIDS 2019, Publish Ahead of Print: &na;. PMID: 30649058, PMCID: PMC6749990, DOI: 10.1097/qad.0000000000002140.Peer-Reviewed Original ResearchConceptsWhite blood countC-statisticBlood countVeterans Aging Cohort Study (VACS) IndexAntiretroviral Therapy Cohort CollaborationDiscrimination of mortalityVACS Index 2.0Antiretroviral therapy initiationCD4 cell countHIV-positive populationHarrell's C-statisticHIV-1 RNAHIV-positive individualsKaplan-Meier plotsCohort CollaborationNadir CD4VAC patientsAntiretroviral therapyCause mortalityCD8 ratioTherapy initiationViral suppressionGeneral healthExcess mortalityLaboratory valuesEmulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV‐positive individuals
Caniglia EC, Robins JM, Cain LE, Sabin C, Logan R, Abgrall S, Mugavero MJ, Hernández‐Díaz S, Meyer L, Seng R, Drozd DR, Seage G, Bonnet F, Le Marec F, Moore RD, Reiss P, Sighem A, Mathews WC, Jarrín I, Alejos B, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Gill J, Pacheco A, Grinsztejn B, Napravnik S, Jose S, Phillips A, Justice A, Tate J, Bucher HC, Egger M, Furrer H, Miro JM, Casabona J, Porter K, Touloumi G, Crane H, Costagliola D, Saag M, Hernán MA. Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV‐positive individuals. Statistics In Medicine 2019, 38: 2428-2446. PMID: 30883859, PMCID: PMC6499640, DOI: 10.1002/sim.8120.Peer-Reviewed Original ResearchConceptsHIV-positive individualsCopies/First-line treatment regimenAIDS Research NetworkAIDS-free survivalCells/Integrated Clinical SystemsHIV-CAUSAL CollaborationOutcomes of interestRisk difference estimatesDirect effectAntiretroviral therapyHIV RNACD4 thresholdTreatment regimenNew regimenTreatment strategiesHIV researchTarget trialsRegimenTherapyResearch NetworkTrialsSurvivalClinical systems
2018
Level of Alcohol Use Associated with HIV Care Continuum Targets in a National U.S. Sample of Persons Living with HIV Receiving Healthcare
Williams EC, McGinnis KA, Edelman EJ, Matson TE, Gordon AJ, Marshall BDL, Bryant KJ, Rubinsky AD, Lapham GT, Satre DD, Richards JE, Catz SL, Fiellin DA, Justice AC, Bradley KA. Level of Alcohol Use Associated with HIV Care Continuum Targets in a National U.S. Sample of Persons Living with HIV Receiving Healthcare. AIDS And Behavior 2018, 23: 140-151. PMID: 29995206, PMCID: PMC6344313, DOI: 10.1007/s10461-018-2210-6.Peer-Reviewed Original ResearchConceptsViral suppressionAlcohol use levelsART treatmentVeterans Aging Cohort Study (VACS) dataAlcohol useAUDIT-C screeningCare continuum outcomesHIV care continuumCohort study dataHigh-level drinkingPoisson regression modelsContinuum outcomesHIV treatmentAdjusted prevalenceCare engagementCare continuumGreater alcohol useHIVPatientsUse levelsTreatmentRegression modelsStudy dataNational U.S. sampleAssociationAssociation of Viral Suppression With Lower AIDS-Defining and Non-AIDS-Defining Cancer Incidence in HIV-Infected Veterans: A Prospective Cohort Study.
Park LS, Tate JP, Sigel K, Brown ST, Crothers K, Gibert C, Goetz MB, Rimland D, Rodriguez-Barradas MC, Bedimo RJ, Justice AC, Dubrow R. Association of Viral Suppression With Lower AIDS-Defining and Non-AIDS-Defining Cancer Incidence in HIV-Infected Veterans: A Prospective Cohort Study. Annals Of Internal Medicine 2018, 169: 87-96. PMID: 29893768, PMCID: PMC6825799, DOI: 10.7326/m16-2094.Peer-Reviewed Original ResearchConceptsLong-term viral suppressionViral suppressionLong-term suppressionCancer incidenceCancer riskHIV treatment successLow viral suppressionViral suppression statusProspective cohort studyT-cell countsEffect of CD4HIV-positive veteransCancer incidence ratesNational InstituteNational Cancer InstituteAIDS definingNon-AIDSUninfected veteransAntiretroviral therapyExcess cancer riskProspective cohortCohort studyUninfected personsIncidence rateTreatment successIncreased non‐AIDS mortality among persons with AIDS‐defining events after antiretroviral therapy initiation
Pettit AC, Giganti MJ, Ingle SM, May MT, Shepherd BE, Gill MJ, Fätkenheuer G, Abgrall S, Saag MS, Del Amo J, Justice AC, Miro JM, Cavasinni M, Dabis F, Monforte AD, Reiss P, Guest J, Moore D, Shepherd L, Obel N, Crane HM, Smith C, Teira R, Zangerle R, Sterne JA, Sterling TR, investigators F. Increased non‐AIDS mortality among persons with AIDS‐defining events after antiretroviral therapy initiation. Journal Of The International AIDS Society 2018, 21: e25031. PMID: 29334197, PMCID: PMC5810321, DOI: 10.1002/jia2.25031.Peer-Reviewed Original ResearchConceptsAdjusted hazard ratioAntiretroviral therapy initiationAIDS mortalityAdjusted hazardCohort CollaborationTherapy initiationAntiretroviral Therapy Cohort CollaborationHIV-1 infectionTreatment-naïve adultsCause of deathMarginal structural modelsART initiationHIV protocolMetabolic deathHazard ratioChronic inflammationRisk factorsCoding CausesSubsequent deathMortalityAIDSCommon pathwayDeathUnmeasured confoundersCause
2017
Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older
Lodi S, Costagliola D, Sabin C, del Amo J, Logan R, Abgrall S, Reiss P, van Sighem A, Jose S, Blanco JR, Hernando V, Bucher HC, Kovari H, Segura F, Ambrosioni J, Gogos CA, Pantazis N, Dabis F, Vandenhende MA, Meyer L, Seng R, Gill MJ, Krentz H, Phillips AN, Porter K, Grinsztejn B, Pacheco AG, Muga R, Tate J, Justice A, Hernán MA. Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2017, 76: 311-318. PMID: 28746165, PMCID: PMC5704899, DOI: 10.1097/qai.0000000000001498.Peer-Reviewed Original ResearchConceptsGeneral HIV populationImmediate initiationHIV populationCD4 countCells/US veteransAIDS mortalityAIDS-free individualsNon-AIDS mortalityUS Veteran cohortHIV-positive individualsHIV-CAUSAL CollaborationAntiretroviral therapyCause mortalityAntiretroviral treatmentMedian ageClinical guidelinesVeteran cohortHigh mortalityMortalityCD4Younger participantsRiskBaselineVeteransAssociation of Cannabis, Stimulant, and Alcohol use with Mortality Prognosis Among HIV-Infected Men
Adams JW, Bryant KJ, Edelman J, Fiellin DA, Gaither JR, Gordon AJ, Gordon KS, Kraemer KL, Mimiaga MJ, Operario D, Tate JP, van den Berg JJ, Justice AC, Marshall BDL. Association of Cannabis, Stimulant, and Alcohol use with Mortality Prognosis Among HIV-Infected Men. AIDS And Behavior 2017, 22: 1341-1351. PMID: 28887669, PMCID: PMC5881942, DOI: 10.1007/s10461-017-1905-4.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyLow-risk alcohol useRisk alcohol useMortality riskAlcohol useStimulant useAdjusted longitudinal analysesAging Cohort StudyUnhealthy alcohol useAssociation of cannabisVACS IndexCause mortalityCohort studyPatient populationPrognostic indicatorMortality prognosisHIVStudy periodSubstance useCannabisRiskLongitudinal analysisMenMortalityStimulantsIncreased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population
Drozd DR, Kitahata MM, Althoff KN, Zhang J, Gange SJ, Napravnik S, Burkholder GA, Mathews WC, Silverberg MJ, Sterling TR, Heckbert SR, Budoff MJ, Van Rompaey S, Delaney JAC, Wong C, Tong W, Palella FJ, Elion RA, Martin JN, Brooks JT, Jacobson LP, Eron JJ, Justice AC, Freiberg MS, Klein DB, Post WS, Saag MS, Moore RD, Crane HM. Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2017, 75: 568-576. PMID: 28520615, PMCID: PMC5522001, DOI: 10.1097/qai.0000000000001450.Peer-Reviewed Original ResearchConceptsTraditional CVD risk factorsDetectable HIV RNACVD risk factorsIncidence rateRisk factorsCD4 countHIV RNAMyocardial infarctionCardiovascular diseaseNorth American AIDS Cohort CollaborationType 1 myocardial infarctionHIV-specific factorsLow CD4 countSuppressive antiretroviral treatmentIncidence rate ratiosCohort CollaborationIncident MINA-ACCORDAggressive managementAntiretroviral treatmentMultivariable analysisAtherosclerosis RiskMI riskCommunity cohortGeneral populationAssociation of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada
Dubrow R, Qin L, Lin H, Hernández-Ramírez RU, Neugebauer RS, Leyden W, Althoff KN, Achenbach CJ, Hessol NA, Modur SP, D'Souza G, Bosch RJ, Grover S, Horberg MA, Kitahata MM, Mayor AM, Novak RM, Rabkin CS, Sterling TR, Goedert JJ, Justice AC, Engels EA, Moore RD, Silverberg MJ. Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2017, 75: 382-390. PMID: 28394855, PMCID: PMC5490794, DOI: 10.1097/qai.0000000000001394.Peer-Reviewed Original ResearchConceptsT-cell countsKS riskCD4 countKaposi's sarcomaART useHIV-1 RNA viral loadNorth American AIDS Cohort CollaborationTime-updated Cox regressionCD4 T-cell countKaposi's sarcoma riskAntiretroviral therapy useRNA viral loadRecent CD4 countViral load measuresAssociation of CD4Cohort CollaborationKS etiologyRecent VLVL measuresAntiretroviral therapyHIV diagnosisIndependent predictorsTherapy useViral loadCox regressionComplementary and Alternative Medicine Among Persons living with HIV in the Era of Combined Antiretroviral Treatment
Halpin SN, Carruth EC, Rai RP, Jennifer Edelman E, Fiellin DA, Gibert C, Gordon KS, Huang W, Justice A, Marconi VC, Rimland D, Perkins MM. Complementary and Alternative Medicine Among Persons living with HIV in the Era of Combined Antiretroviral Treatment. AIDS And Behavior 2017, 22: 848-852. PMID: 28733920, PMCID: PMC5939585, DOI: 10.1007/s10461-017-1866-7.Peer-Reviewed Original ResearchConceptsCAM useAlternative medicineVeterans Aging Cohort StudyAntiretroviral therapy eraCombined Antiretroviral TreatmentAging Cohort StudyTherapy eraBothersome symptomsCohort studyAntiretroviral treatmentCAM usersHigh prevalenceMore benzodiazepinesLess nicotineHIVTraditional treatmentPLWHCliniciansTreatmentMedicineOpioidsSymptomsBenzodiazepinesPrevalenceNicotineCD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC)
Trickey A, May MT, Schommers P, Tate J, Ingle SM, Guest JL, Gill MJ, Zangerle R, Saag M, Reiss P, Monforte A, Johnson M, Lima VD, Sterling TR, Cavassini M, Wittkop L, Costagliola D, Sterne JAC, Boulle A, Stephan C, Miro J, Cavassini M, Chêne G, Costagliola D, Dabis F, Monforte A, del Amo J, Van Sighem A, Vehreschild J, Gill J, Guest J, Haerry D, Hogg R, Justice A, Shepherd L, Obel N, Crane H, Smith C, Reiss P, Saag M, Sterling T, Teira R, Williams M, Zangerle R, Sterne J, May M, Ingle S, Trickey A. CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). Clinical Infectious Diseases 2017, 65: 959-966. PMID: 28903507, PMCID: PMC5850630, DOI: 10.1093/cid/cix466.Peer-Reviewed Original ResearchConceptsAdjusted hazard ratioCD8 countsCD8 ratioCohort CollaborationAntiretroviral therapyCause mortalityCD4 countHazard ratioMiddle tertilePrognostic markerAIDS mortalityCause-specific mortality hazard ratiosAntiretroviral Therapy Cohort CollaborationHigher CD4 countsMortality hazard ratioCells/μLHuman immunodeficiency virusIndependent prognostic markerNorth American cohortAssociation of CD8Shape of associationsAssociation of CD4Immunodeficiency virusHuman immunodeficiencyCD4Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
Collaboration T, Trickey A, May M, Vehreschild J, Obel N, Gill M, Crane H, Boesecke C, Patterson S, Grabar S, Cazanave C, Cavassini M, Shepherd L, Monforte A, van Sighem A, Saag M, Lampe F, Hernando V, Montero M, Zangerle R, Justice A, Sterling T, Ingle S, Sterne J. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. The Lancet HIV 2017, 4: e349-e356. PMID: 28501495, PMCID: PMC5555438, DOI: 10.1016/s2352-3018(17)30066-8.Peer-Reviewed Original ResearchConceptsInitiation of ARTAntiretroviral therapyART initiationCause mortalityHazard ratioLife expectancyCalendar periodCause-specific mortality hazard ratiosYears of ARTFirst yearHIV-1 cohortToxic antiretroviral drugsCombination antiretroviral therapyHIV-positive patientsCD4 cell countManagement of comorbiditiesMortality hazard ratioUK Medical Research CouncilHealth care plannersMedical Research CouncilEDCTP2 programmeCohort studyViral loadAntiretroviral drugsYear survivalAssociation Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study
Freiberg MS, Chang CH, Skanderson M, Patterson OV, DuVall SL, Brandt CA, So-Armah KA, Vasan RS, Oursler KA, Gottdiener J, Gottlieb S, Leaf D, Rodriguez-Barradas M, Tracy RP, Gibert CL, Rimland D, Bedimo RJ, Brown ST, Goetz MB, Warner A, Crothers K, Tindle HA, Alcorn C, Bachmann JM, Justice AC, Butt AA. Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study. JAMA Cardiology 2017, 2: 536-546. PMID: 28384660, PMCID: PMC5541383, DOI: 10.1001/jamacardio.2017.0264.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsCase-Control StudiesCD4 Lymphocyte CountCohort StudiesFemaleHeart FailureHIV InfectionsHumansMaleMiddle AgedProportional Hazards ModelsRisk AssessmentRisk FactorsRisk Reduction BehaviorStroke VolumeUnited StatesUnited States Department of Veterans AffairsVeteransViral LoadConceptsRisk of HFrEFHuman immunodeficiency virus (HIV) infectionVeterans Aging Cohort StudyAntiretroviral therapy eraRisk of HFpEFReduced ejection fractionCells/mm3Immunodeficiency virus infectionHeart failureAging Cohort StudyHIV infectionEjection fractionUninfected veteransTherapy eraCohort studyVirus infectionHIV-1 RNA viral loadTime-updated CD4 cell countHIV-specific factorsBaseline cardiovascular diseaseCD4 cell countRNA viral loadCopies/mLRace/ethnicityObservational cohortComparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study
Caniglia EC, Cain LE, Sabin CA, Robins JM, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage GR, Bonnet F, Dabis F, Moore RD, Reiss P, van Sighem A, Mathews WC, del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Justice AC, Tate JP, Gill J, Pacheco A, Veloso VG, Bucher HC, Egger M, Furrer H, Porter K, Touloumi G, Crane H, Miro JM, Sterne JA, Costagliola D, Saag M, Hernán MA, Collaboration H, Systems C. Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. The Lancet HIV 2017, 4: e251-e259. PMID: 28411091, PMCID: PMC5492888, DOI: 10.1016/s2352-3018(17)30043-7.Peer-Reviewed Original ResearchConceptsCD4 cell countHIV-positive individualsVirological failureHazard ratioCell countViral loadRisk ratioObservational studyTime-varying CD4 cell countHIV RNA viral loadAntiretroviral therapy regimenCombination antiretroviral therapyRNA viral loadAIDS Research NetworkMortality hazard ratioIntegrated Clinical SystemsHIV-CAUSAL CollaborationLong-term safetyCell count differencesAntiretroviral therapyCD4 countTherapy regimenProspective studyImmunological outcomesClinical guidelines